Century Therapeutics, Inc. financial data

Symbol
IPSC on Nasdaq
Location
Philadelphia, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 365% % -66%
Debt-to-equity 52% % -45%
Return On Equity -13% % 80%
Return On Assets -9% % 74%
Operating Margin -28% % 100%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 87,307,091 shares 2.7%
Common Stock, Shares, Outstanding 86,527,767 shares 2.3%
Entity Public Float $212,506,473 USD 61%
Common Stock, Value, Issued $9,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 86,464,066 shares 2.1%
Weighted Average Number of Shares Outstanding, Diluted 86,464,066 shares 2.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $114,898,000 USD 8287%
General and Administrative Expense $30,802,000 USD -9.4%
Operating Income (Loss) $33,896,000 USD 77%
Nonoperating Income (Expense) $9,197,000 USD -34%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $24,699,000 USD 81%
Income Tax Expense (Benefit) $1,790,000 USD -4.8%
Net Income (Loss) Attributable to Parent $26,474,000 USD 80%
Earnings Per Share, Basic 0 USD/shares 84%
Earnings Per Share, Diluted 0 USD/shares 84%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $55,515,000 USD 5.6%
Assets, Current $137,709,000 USD -33%
Property, Plant and Equipment, Net $53,715,000 USD -18%
Operating Lease, Right-of-Use Asset $16,566,000 USD -43%
Intangible Assets, Net (Excluding Goodwill) $34,200,000 USD 1.2%
Goodwill $4,727,000 USD
Assets $244,717,000 USD -37%
Accounts Payable, Current $2,617,000 USD 0.73%
Employee-related Liabilities, Current $3,537,000 USD -43%
Liabilities, Current $22,026,000 USD 11%
Deferred Income Tax Liabilities, Net $4,374,000 USD 25%
Operating Lease, Liability, Noncurrent $41,185,000 USD -19%
Liabilities $68,369,000 USD -65%
Accumulated Other Comprehensive Income (Loss), Net of Tax $64,000 USD -92%
Retained Earnings (Accumulated Deficit) $772,740,000 USD -3.5%
Stockholders' Equity Attributable to Parent $176,348,000 USD -9.9%
Liabilities and Equity $244,717,000 USD -37%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $34,623,000 USD -14%
Net Cash Provided by (Used in) Financing Activities $120,000 USD -99%
Net Cash Provided by (Used in) Investing Activities $27,930,000 USD 142%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 86,527,767 shares 2.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $58,674,000 USD 5.8%
Deferred Tax Assets, Valuation Allowance $192,229,000 USD 51%
Deferred Tax Assets, Gross $208,724,000 USD 51%
Operating Lease, Liability $44,957,000 USD -18%
Depreciation $12,870,000 USD -4.9%
Payments to Acquire Property, Plant, and Equipment $475,000 USD -12%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $27,168,000 USD 79%
Lessee, Operating Lease, Liability, to be Paid $66,399,000 USD -24%
Property, Plant and Equipment, Gross $99,324,000 USD 1.3%
Operating Lease, Liability, Current $3,772,000 USD 0.35%
Lessee, Operating Lease, Liability, to be Paid, Year Two $7,377,000 USD -24%
Lessee, Operating Lease, Liability, to be Paid, Year One $7,340,000 USD 206%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $21,442,000 USD -24%
Lessee, Operating Lease, Liability, to be Paid, Year Three $7,565,000 USD -19%
Deferred Tax Assets, Operating Loss Carryforwards $61,112,000 USD 97%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $7,756,000 USD -19%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $16,495,000 USD 59%
Share-based Payment Arrangement, Expense $8,199,000 USD -40%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%